多西他赛与紫杉醇脂质体两种新辅助化疗方案分别联合手术治疗晚期食管癌的效果对比  

Comparison of the Effects of Docetaxel and Paclitaxel Liposome Two Neoadjuvant Chemotherapy Regimens Combined with Surgery in the Treatment of Advanced Esophageal Cancer

作　　者：吕本博 丁国文[1] LV Benbo;DING Guowen(Department of Cardiothoracic Surgery,Affiliated People’s Hospital of Jiangsu University,Zhenjiang 212002,Jiangsu,China)

机构地区：[1]江苏大学附属人民医院胸心外科,江苏镇江212002

出　　处：《中国药物滥用防治杂志》2024年第1期84-87,91,共5页Chinese Journal of Drug Abuse Prevention and Treatment

基　　金：2022年度镇江市科技计划项目(编号:SH2022041)。

摘　　要：目的:对比局部晚期食管癌患者采用紫杉醇脂质体与多西他赛新辅助化疗联合手术治疗的临床效果。方法:回顾性收集2013年1月—2023年5月江苏大学附属人民医院胸心外科收治的40例局部晚期食管癌患者的临床资料,根据新辅助化疗方案的不同分为观察组(21例,紫杉醇脂质体+铂类方案)和对照组(19例,多西他赛+铂类方案),均持续治疗2个疗程。比较两组临床疗效、R0切除率、肿瘤标志物水平[鳞状细胞癌抗原(SCC-Ag)、癌胚抗原(CEA)]、围术期指标及治疗期间副作用发生情况和随访期间生存情况。结果:两组R0切除率、缓解率、血清CEA、SCC-Ag、术中出血量、手术时间、术后胸腔引流液比较,差异无统计学意义(P>0.05);治疗期间,对照组过敏、白细胞减少发生率高于观察组(P<0.05);随访24个月内,观察组总生存率为47.62%(10/21),对照组患者总生存率为47.37%(9/19),经Log Rank检验,两组总生存期比较,差异无统计学意义(P>0.05)。结论:局部晚期食管癌患者采用紫杉醇脂质体与多西他赛新辅助化疗联合手术治疗的治疗效果相当,但紫杉醇脂质体新辅助化疗的副作用较低。Objective:To compare the clinical effects of paclitaxel liposome and docetaxel neoadjuvant chemotherapy combined with surgery in patients with locally advanced esophageal cancer.Methods:The clinical data of 40 patients with locally advanced esophageal cancer admitted to the Department of Thoracic and Cardiovascular Surgery,Affiliated People’s Hospital of Jiangsu University from January 2013 to May 2023 were retrospectively collected.According to the different neoadjuvant chemotherapy regimens,they were divided into observation group(21 patients,paclitaxel liposome+platinum regimen)and control group(19 patients,docetaxel+platinum regimen).Both groups were treated continuously for 2 courses.The clinical efficacy,R0 resection rate,tumor marker levels[squamous cell carcinoma antigen(SCC-Ag),carcinoembryonic antigen(CEA)],perioperative indicators,side effects during treatment and survival during follow-up were compared between the two groups.Results:There was no significant difference in R0 resection rate,remission rate,serum CEA,SCC-Ag,intraoperative blood loss,operation time and postoperative thoracic drainage between the two groups(P>0.05).During the treatment,the incidence of allergy and leukopenia in the control group was higher than that in the observation group(P<0.05).Within 24 months of follow-up,the total survival rate of the observation group was 47.62%(10/21),and the total survival rate of the control group was 47.37%(9/19).The Log Rank test showed that there was no significant difference in the total survival time between the two groups(P>0.05).Conclusion:The therapeutic effect of paclitaxel liposome and docetaxel neoadjuvant chemotherapy combined with surgery in patients with locally advanced esophageal cancer is similar,but the side effects of paclitaxel liposome neoadjuvant chemotherapy are lower.

关 键 词：多西他赛 紫杉醇脂质体 新辅助化疗 晚期食管癌 

分 类 号：R735.1[医药卫生—肿瘤]